OpenLB
Open Library of Bioscience
Advanced Search
Antimicrobial agents and chemotherapy
Mar, 2013;57 (3): 1283-90.

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus.

Jabeen Noore, Adly Noore, Bingyun Li
Author Information
  1. Jabeen Noore: Department of Orthopaedics, School of Medicine, West Virginia University, Morgantown, WV, USA.
PMID: 23274662 DOI: 10.1128/AAC.01650-12

Abstract

The increasing resistance of bacteria to conventional antibiotics and the challenges posed by intracellular bacteria, which may be responsible for chronic and recurrent infections, have driven the need for advanced antimicrobial drugs for effective elimination of both extra- and intracellular pathogens. The purpose of this study was to determine the killing efficacy of cationic antimicrobial peptide LL-37 compared to conventional antibiotics against extra- and intracellular Staphylococcus aureus. Bacterial killing assays and an infection model of osteoblasts and S. aureus were studied to determine the bacterial killing efficacy of LL-37 and conventional antibiotics against extra- and intracellular S. aureus. We found that LL-37 was effective in killing extracellular S. aureus at nanomolar concentrations, while lactoferricin B was effective at micromolar concentrations and doxycycline and cefazolin at millimolar concentrations. LL-37 was surprisingly more effective in killing the clinical strain than in killing an ATCC strain of S. aureus. Moreover, LL-37 was superior to conventional antibiotics in eliminating intracellular S. aureus. The kinetic studies further revealed that LL-37 was fast in eliminating both extra- and intracellular S. aureus. Therefore, LL-37 was shown to be very potent and prompt in eliminating both extra- and intracellular S. aureus and was more effective in killing extra- and intracellular S. aureus than commonly used conventional antibiotics. LL-37 could potentially be used to treat chronic and recurrent infections due to its effectiveness in eliminating not only extracellular but also intracellular pathogens.

References

  1. Trends Immunol. 2002 Jun;23(6):291-6 [PMID: 12072367]
  2. Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):100-6 [PMID: 1864271]
  3. J Antimicrob Chemother. 2006 Feb;57(2):260-5 [PMID: 16387752]
  4. Antimicrob Agents Chemother. 2004 Feb;48(2):546-55 [PMID: 14742208]
  5. Microb Pathog. 1995 Dec;19(6):409-19 [PMID: 8852281]
  6. J Bone Joint Surg Am. 2005 Jun;87(6):1343-7 [PMID: 15930546]
  7. Clin Microbiol Infect. 2001;7 Suppl 4:8-15 [PMID: 11688538]
  8. Trends Immunol. 2009 Mar;30(3):131-41 [PMID: 19217824]
  9. N Engl J Med. 2009 Jan 29;360(5):439-43 [PMID: 19179312]
  10. J Control Release. 2008 Feb 11;125(3):210-27 [PMID: 18077047]
  11. Antimicrob Agents Chemother. 1998 Sep;42(9):2206-14 [PMID: 9736536]
  12. J Antimicrob Chemother. 2003 May;51(5):1159-65 [PMID: 12697647]
  13. Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S344-9 [PMID: 18462089]
  14. Clin Infect Dis. 2004 Apr 15;38(8):1075-83 [PMID: 15095210]
  15. Clin Infect Dis. 2006 Oct 15;43(8):961-7 [PMID: 16983605]
  16. Int J Artif Organs. 2011 Sep;34(9):789-98 [PMID: 22094558]
  17. Antimicrob Agents Chemother. 2005 Jul;49(7):2845-50 [PMID: 15980359]
  18. Trends Microbiol. 2009 Feb;17(2):59-65 [PMID: 19208480]
  19. Int J Mol Sci. 2011;12(9):5971-92 [PMID: 22016639]
  20. Biomaterials. 2009 May;30(13):2552-8 [PMID: 19215980]
  21. J Mol Med (Berl). 2007 Apr;85(4):317-29 [PMID: 17216206]
  22. Infect Immun. 1999 May;67(5):2677-81 [PMID: 10225942]
  23. Microb Pathog. 1999 Jun;26(6):317-23 [PMID: 10343060]
  24. Nat Rev Microbiol. 2006 Jul;4(7):529-36 [PMID: 16778838]
  25. Drug Discov Today. 2003 Feb 1;8(3):107-10 [PMID: 12568776]
  26. Biopolymers. 2000;55(1):4-30 [PMID: 10931439]
  27. Int J Med Microbiol. 2010 Feb;300(2-3):170-5 [PMID: 19781990]
  28. Methods Mol Biol. 2012;794:169-83 [PMID: 21956562]
  29. N Engl J Med. 2005 Apr 7;352(14):1485-7 [PMID: 15814886]
  30. Antimicrob Agents Chemother. 2003 Nov;47(11):3407-14 [PMID: 14576095]
  31. Postgrad Med J. 2000 Aug;76(898):479-83 [PMID: 10908375]
  32. J Orthop Res. 2010 Jan;28(1):48-54 [PMID: 19588527]
  33. J Intern Med. 2004 Apr;255(4):519-20 [PMID: 15049887]
  34. Eur J Immunol. 2010 Apr;40(4):1118-26 [PMID: 20140902]
  35. J Bone Joint Surg Br. 2003 Aug;85(6):918-21 [PMID: 12931819]
  36. Medicine (Baltimore). 2003 Sep;82(5):333-9 [PMID: 14530782]
  37. Pediatr Infect Dis J. 2004 Aug;23(8):701-6 [PMID: 15295218]
  38. Infect Agents Dis. 1994 Dec;3(6):302-12 [PMID: 7889317]
  39. Antimicrob Agents Chemother. 1994 May;38(5):1059-64 [PMID: 8067738]
  40. Trends Microbiol. 2000 Sep;8(9):402-10 [PMID: 10989307]
  41. Infect Immun. 2001 May;69(5):2872-7 [PMID: 11292701]
  42. J Biol Chem. 1998 Feb 6;273(6):3718-24 [PMID: 9452503]
  43. J Am Chem Soc. 2002 Jun 26;124(25):7324-30 [PMID: 12071741]
  44. Virulence. 2010 Sep-Oct;1(5):440-64 [PMID: 21178486]
  45. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):381-90; quiz 391-2 [PMID: 15761415]
  46. Cell Mol Life Sci. 2011 Jul;68(13):2161-76 [PMID: 21573784]
  47. J Dermatol Sci. 2005 Nov;40(2):123-32 [PMID: 15963694]
  48. Biochim Biophys Acta. 1999 Dec 15;1462(1-2):55-70 [PMID: 10590302]
  49. Curr Drug Targets Infect Disord. 2002 Mar;2(1):79-83 [PMID: 12462155]
  50. Immunol Res. 2004;30(3):291-308 [PMID: 15531771]
  51. J Antimicrob Chemother. 2002 Oct;50(4):461-7 [PMID: 12356789]
  52. J Microbiol Methods. 2001 Mar 1;44(2):121-9 [PMID: 11165341]
  53. Crit Rev Immunol. 2000;20(5):407-31 [PMID: 11145218]
  54. Nat Nanotechnol. 2009 Jul;4(7):457-63 [PMID: 19581900]
  55. Antimicrob Agents Chemother. 2010 Oct;54(10):4049-58 [PMID: 20696877]
  56. Nat Biotechnol. 2006 Dec;24(12):1551-7 [PMID: 17160061]
  57. JAMA. 2007 Oct 17;298(15):1763-71 [PMID: 17940231]
  58. Scand J Infect Dis. 2003;35(11-12):782-9 [PMID: 14723349]
  59. Rev Med Interne. 2004 Sep;25(9):629-35 [PMID: 15363618]
  60. Pediatr Infect Dis J. 2004 Mar;23(3):255-7 [PMID: 15014303]
  61. Trends Microbiol. 2009 Feb;17(2):54-8 [PMID: 19162480]
  62. Clin Immunol. 2010 Apr;135(1):1-11 [PMID: 20116332]
  63. J Invest Dermatol. 2003 May;120(5):810-6 [PMID: 12713586]
  64. Arch Intern Med. 2002 Jan 14;162(1):25-32 [PMID: 11784216]
  65. Nature. 2002 Jan 24;415(6870):389-95 [PMID: 11807545]
  66. Int J Nanomedicine. 2011;6:3281-93 [PMID: 22228996]
  67. J Trauma. 2011 Aug;71(2 Suppl 2):S235-57 [PMID: 21814090]
  68. Biochemistry. 1999 Jun 1;38(22):7235-42 [PMID: 10353835]
  69. Arch Immunol Ther Exp (Warsz). 2010 Feb;58(1):15-25 [PMID: 20049649]
  70. Clin Infect Dis. 2001 Jun 1;32(11):1643-7 [PMID: 11340539]
  71. Pediatr Surg Int. 2005 Jan;21(1):20-4 [PMID: 15645239]
  72. Antimicrob Agents Chemother. 1985 May;27(5):874-5 [PMID: 4015078]
  73. Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):114-8 [PMID: 1864273]
  74. Antimicrob Agents Chemother. 2012 Feb;56(2):845-56 [PMID: 22083479]
  75. J Orthop Res. 2012 Feb;30(2):196-202 [PMID: 21815205]

Grants

  1. P20 RR016440/NCRR NIH HHS
  2. P20 RR016477/NCRR NIH HHS
  3. 5P20RR016477/NCRR NIH HHS

MeSH Term

Animals
Anti-Bacterial Agents
Antimicrobial Cationic Peptides
Cathelicidins
Cefazolin
Cell Line, Tumor
Dose-Response Relationship, Drug
Doxycycline
Kinetics
Lactoferrin
Microbial Sensitivity Tests
Osteoblasts
Rats
Staphylococcus aureus

Chemicals

Anti-Bacterial Agents
Antimicrobial Cationic Peptides
Cathelicidins
lactoferricin B
Lactoferrin
Cefazolin
Doxycycline
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.
Article has an altmetric score of 6

Word Cloud

Created with Highcharts 10.0.0intracellularaureusLL-37Sextra-killingeffectiveconventionalantibioticseliminatingantimicrobialconcentrationsbacteriachronicrecurrentinfectionspathogensdetermineefficacypeptideStaphylococcusextracellularstrainusedincreasingresistancechallengesposedmayresponsibledrivenneedadvanceddrugseliminationpurposestudycationiccomparedBacterialassaysinfectionmodelosteoblastsstudiedbacterialfoundnanomolarlactoferricinBmicromolardoxycyclinecefazolinmillimolarsurprisinglyclinicalATCCMoreoversuperiorkineticstudiesrevealedfastThereforeshownpotentpromptcommonlypotentiallytreatdueeffectivenessalsoCationic

Similar Articles

Cited By